DXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results for the half year ending 31 October 2025. H1 2025 Financial highlights: Core recurring revenue model remains resilient. Revenue decreased by 2.6% to £1,684,712 (H1 2024 - £1,730,829) in the six months to 31 October 2025 ("Period"). Administration costs decreased by 5% in the Period (H1 2024 - ...

此外，针对SELECT研究数据的二次分析结果显示：在治疗早期，司美格鲁肽注射液(商品名：诺和盈)就已显示出对心脏的保护 作用，早于明显的体重减轻。这一发现提示，无论体重降幅，使用司美格鲁肽注射液(商品名：诺和盈)均实现降低MACE风险的 获益。 真实世界研究作为创新药物的"试金石"，基于患者实际用药经历所得的证据，成为随机对照试验的重要补充。一项回顾性、观 察性真实世界研究STEER研究显示，与替尔泊肽相比，持续接受司美格鲁肽注射液(商品名：诺和盈)治疗的超重/肥胖且已确诊 心血管疾病的患者心脏病发作、卒中以及全因死亡的风险显著降低57%。同时，STEER研究结果提供了更多的证据，表明司美 格鲁肽注射液(商品名：诺和盈)所展现的心脏保护获益可能为司美格鲁肽分子独有，因此无法拓展至其他GLP-1或GIP/GLP-1类 药物。 司美格鲁肽注射液(商品名：诺和盈) 在中国，每年约有400万人死于心血管疾病，占总死亡人数的40%以上，是伤残和寿命损失的重要原因。而肥胖症作为心血管疾 病的独立危险因素，能直接导致心血管发病率、死亡率和住院率的上升。在肥胖人群中，三分之二的死亡由心血管疾病引起。 此外，我国肥胖患者以腹型 ...

Core Insights - The Ninth Hu-Lu Cardiovascular Disease Expert Forum and several other significant academic meetings were held in Rizhao, focusing on advancements in cardiovascular disease treatment and collaboration among experts in the field [1][5][9]. Group 1: Event Overview - The event included multiple important academic activities such as the Hu-Lu Cardiovascular Disease Expert Forum, the 21st CTOCC meeting, and the first session of the CCI Innovation Academy, aimed at integrating high-quality resources and enhancing efficiency in cardiovascular medicine [9][10]. - The forum has evolved over nine years into a prestigious academic event, emphasizing the core values of inheritance, innovation, cooperation, and talent cultivation in the medical field [5][7]. Group 2: Expert Contributions - Key experts, including Professor Ge Junbo and Professor Huo Yong, highlighted the importance of multi-conference collaboration in advancing cardiovascular medicine and fostering regional cooperation [7][9]. - The event showcased successful demonstrations of complex chronic total occlusion (CTO) surgeries, emphasizing the application of innovative techniques and the sharing of clinical experiences among top experts [12][14]. Group 3: Institutional Achievements - The Qingdao University Affiliated Rizhao Hospital has completed over 20,000 surgeries in seven years, establishing itself as a trusted institution in the region and achieving significant technical breakthroughs [9][16]. - The hospital has introduced numerous new techniques, including several firsts in Shandong province, reinforcing its commitment to advancing cardiovascular care and ensuring public health [16].

Group 1 - Novo Nordisk has entered the Indian market with its weight loss drug Wegovy, which has been approved for long-term chronic weight management and reducing the risk of major cardiovascular events [1][2] - Wegovy will be available in five dosages, with the starting dose of 0.25 mg priced at 4,336.25 INR (approximately 50.3 USD) and the highest dose of 2.4 mg priced at 6,503.75 INR, significantly lower than its US price of 337.25 USD [1] - The introduction of Wegovy follows a recommendation from the American College of Cardiology to use semaglutide as a first-line treatment for cardiovascular diseases, addressing a significant health issue in India where heart disease is a leading cause of death [2] Group 2 - Novo Nordisk aims to collaborate with insurance companies and financial institutions to enhance the affordability and accessibility of Wegovy, and is considering partnerships with local companies for further product promotion [3] - The market for weight loss therapies in India is growing, as evidenced by a 60% month-on-month increase in sales of Eli Lilly's Mounjaro since its launch, indicating strong consumer interest in such treatments [3] - Novo Nordisk plans to introduce its next-generation anti-obesity candidates, CagriSema and amycretin, which are currently in clinical trials, and is preparing for the market after the expiration of the semaglutide patent in Q2 2026 [3]

Core Insights - Jiangsu Hengrui Medicine Co., Ltd. has signed a collaboration agreement with Merck to license its oral small molecule drug targeting lipoprotein(a) (HRS-5346) for a payment of $200 million upfront [3][4] - The agreement allows Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 outside Greater China, with potential milestone payments reaching up to $1.77 billion and additional sales royalties based on performance [3][4] - HRS-5346 is currently undergoing Phase II clinical trials in China and targets elevated Lp(a) levels, which are linked to cardiovascular diseases [4][5] Financial Implications - The total potential revenue for Hengrui from this collaboration could approach $2 billion, including upfront payments, milestone payments, and sales royalties [3][4] - Hengrui has previously engaged in 12 licensing deals since 2018, totaling approximately $12 billion, with upfront payments around $400 million [4] Strategic Importance - This partnership is expected to enhance Hengrui's international market presence and improve its innovative brand and overseas performance [5] - The collaboration aligns with Hengrui's strategy of balancing in-house development with external partnerships to accelerate the global reach of its innovative products [5]